Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01894295

Enrollment

Registered

2013-07-10

Start date

2012-06-30

Completion date

2013-09-30

Last updated

2013-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Vitamin D analogues, Resting Metabolic rate, obesity

Brief summary

The aim of this double blind clinical trial study is to investigate whether alphacalcidol treatment in obese subjects can affect the resting metabolic rate. Moreover, the investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated receptor gamma (PPARγ) and eroxisome proliferator-activated receptor- coactivator-1 α (PGC1α) protein which may lead to change in metabic rate following treatment with either alphacalcidol or placebo.

Interventions

DIETARY_SUPPLEMENTPlacebo

Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks

DIETARY_SUPPLEMENTVitamin D analogue

1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

22 Years to 52 Years

Healthy volunteers

Yes

Inclusion criteria

Age 22-52 years Body mass index equal or more than 30

Exclusion criteria

Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse History of any condition affecting inflammatory markers Thyroid diseases Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic infections Hepatic or renal diseases Use of PPARγ agonist drug

Design outcomes

Primary

Measure	Time frame	Description
Resting Metabolic Rate	Change from baseline to 8 weeks	Measurement by indirect calorimetry.

Secondary

Measure	Time frame	Description
Changes of Nesfatin-1, PPARγ and PGC1α protein levels	Change from baseline to 8 weeks	Measurement by ELISA kit

Other

Measure	Time frame	Description
Change of ACS and FASN Enzymes	Change from baseline to 8 weeks	Measurement by ELISA kit

Countries

Iran

Contacts

Primary ContactMahmoud Jalali, Phd

jalalimahmoud@hotmail.com+982188954911

Backup ContactKhadijeh Mirzaei, MS

mina_mirzaei101@yahoo.com+989124379670

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026